Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CYT107 for Immune Restoration in Lymphopenic COVID-19 Patients
NCT04407689Phase 2Terminated
- Sponsor
- RevImmune
- Start
- Jun 2020
- Primary completion
- Mar 2022
- Modality
- Cytokines & Interferons
- Countries
- 1
01
Overview
A Phase 2 trial of recombinant human interleukin-7 in coronavirus disease 2019 (COVID-19), sponsored by RevImmune. Started Jun 2020; status: terminated.
02
Drugs
recombinant human interleukin-7
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04407689.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04407689.